Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized 6-week safety, tolerability, and pharmacokinetics study of asenapine in elderly subjects with psychosis
2006-005585-40Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of asenapine in schizophrenia and bipolar I disorder, sponsored by Organon & Co. Primary endpoints: Safety and tolerability over 6 weeks and Pharmacokinetic/pharmacodynamic relationship. Started Jan 2007; status: completed.
02
Drugs
asenapine
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on 2006-005585-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005585-40.